Safety and efficacy of tranexamic acid and beta-blockers for traumatic brain injury: A systematical review and meta-analysis.
Surgical Neurology International · 2026-01-01 · Meta-analysis
Abstract
BACKGROUND: Intracranial hemorrhage is a leading cause of secondary brain injury following traumatic brain injury (TBI). Tranexamic acid (TXA), an antifibrinolytic agent, is recommended by Advanced Trauma Life Support for hemorrhagic trauma, but its role in TBI remains debated. Recent meta-analyses and randomized controlled trials (RCTs) have demonstrated conflicting results regarding TXA's mortality benefits, while beta-blockers (BBs) show potential in mitigating hyperadrenergic states post-TBI. This study aims to update the evidence on TXA and BB administration in TBI by incorporating newer RCTs and systematic reviews published post-February 2023. METHODS: A systematic search of PubMed, ScienceDirect, and clinicaltrials.gov was conducted using keywords: "tranexamic acid," "beta blockers," and "traumatic brain injury." Studies published up to December 2024 were included to address gaps in the literature. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed, and data were analyzed using RevMan 5. Primary outcomes were the safety and efficacy of TXA and BB. RESULTS: Thirteen RCTs (n = 16,452) were included, expanding on prior meta-analyses. TXA did not significantly reduce mortality (relative risk 0.93, 95% confidence intervals [CI] 0.86-1.01) but reduced hematoma progression (mean difference -3.67 cm3,*P* = 0.007). BB showed a non-significant mortality reduction (13.65% vs. 18.34%; Odds ratio [OR] 0.55 [95% CI 0.27-1.13]). Adverse events were comparable between groups. CONCLUSION: TXA and BB are safe but do not significantly improve mortality in TBI. Our updated analysis aligns with recent literature, underscoring the need for further RCTs to clarify subgroups (e.g., mild-moderate TBI) that may benefit.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Cardiovascular drugs · Haemostatics · Mortality & survival · Tranexamic acid
Related articles
- Comparative effectiveness and safety of pharmacological interventions for secondary brain injury in adult traumatic brain injury: a network meta-analysis of randomized trials. (BMC Neurol, 2026)
- Tranexamic acid for neurological outcomes and mortality in adults with hemorrhagic acute brain injury: an updated systematic review and meta-analysis of randomized controlled trials. (Front Neurol, 2026)
- Relationship between Tranexamic Acid Use and Safety in Patients with Acute Brain Injury: A Systematic Review and Meta-analysis of Mortality and Thromboembolic Events. (CNS Drugs, 2025)
- Is tranexamic acid effective for all traumatic brain injury patients? a severity based systematic review and meta-analysis. (Front Pharmacol, 2025)
- Tranexamic acid in the management of traumatic brain injury: a systematic review and meta-analysis with trial sequential analysis. (Einstein (Sao Paulo), 2025)
- Optimal dose of tranexamic acid in traumatic brain injury: Systematic review and network meta-analysis of randomized controlled trials. (J Trauma Acute Care Surg, 2025)